247 related articles for article (PubMed ID: 9536660)
1. Influence of caffeine on pharmacokinetic profile of sodium valproate and carbamazepine in normal human volunteers.
Vaz J; Kulkarni C; David J; Joseph T
Indian J Exp Biol; 1998 Jan; 36(1):112-4. PubMed ID: 9536660
[TBL] [Abstract][Full Text] [Related]
2. Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers.
Kulkarni C; Vaz J; David J; Joseph T
Indian J Physiol Pharmacol; 1995 Apr; 39(2):122-6. PubMed ID: 7649598
[TBL] [Abstract][Full Text] [Related]
3. Effect of treatment and additional disease on pharmacokinetic of valproic acid in children with epilepsy.
Juárez-Olguín H; Lugo-Goytia G; Flores-Murrieta F; Ruiz-García M; Lares Asseff I; Flores Pérez J
Rev Invest Clin; 2010; 62(6):516-23. PubMed ID: 21416779
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic interactions of valproate, phenytoin, phenobarbitone and carbamazepine with curcumin in experimental models of epilepsy in rats.
Reeta KH; Mehla J; Pahuja M; Gupta YK
Pharmacol Biochem Behav; 2011 Sep; 99(3):399-407. PubMed ID: 21641922
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic modeling of carbamazepine based on clinical data from Serbian epileptic patients.
Jankovic SM; Jovanovic D; Milovanovic JR
Methods Find Exp Clin Pharmacol; 2008 Nov; 30(9):707-13. PubMed ID: 19229380
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.
Wangemann M; Retzow A; Vens-Cappell B
Int J Clin Pharmacol Ther; 1999 Feb; 37(2):100-8. PubMed ID: 10082174
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic interaction of brivaracetam on carbamazepine in adult patients with epilepsy, with and without valproate co-administration.
Stockis A; Sargentini-Maier ML; Brodie MJ
Epilepsy Res; 2016 Dec; 128():163-168. PubMed ID: 27842261
[TBL] [Abstract][Full Text] [Related]
8. Effect of carbamazepine and valproate on bone mineral density.
Ecevit C; Aydoğan A; Kavakli T; Altinöz S
Pediatr Neurol; 2004 Oct; 31(4):279-82. PubMed ID: 15464641
[TBL] [Abstract][Full Text] [Related]
9. N-(anilinomethyl)-p-isopropoxyphenylsuccinimide potentiates the anticonvulsant action of phenobarbital and valproate in the mouse maximal electroshock-induced seizure model.
Luszczki JJ; Kocharov SL; Czuczwar SJ
Neurosci Res; 2009 Jul; 64(3):267-72. PubMed ID: 19447295
[TBL] [Abstract][Full Text] [Related]
10. Influence of food on the bioavailability of a carbamazepine slow-release formulation.
Retzow A; Schürer M; Schulz HU
Int J Clin Pharmacol Ther; 1997 Dec; 35(12):557-60. PubMed ID: 9455713
[TBL] [Abstract][Full Text] [Related]
11. Investigation of low levels of plasma valproic acid concentration following simultaneous administration of sodium valproate and rizatriptan benzoate.
Hokama N; Hobara N; Kameya H; Ohshiro S; Hobara N; Sakanashi M
J Pharm Pharmacol; 2007 Mar; 59(3):383-6. PubMed ID: 17331341
[TBL] [Abstract][Full Text] [Related]
12. Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.
Garg SK; Kumar N; Bhargava VK; Prabhakar SK
Clin Pharmacol Ther; 1998 Sep; 64(3):286-8. PubMed ID: 9757152
[TBL] [Abstract][Full Text] [Related]
13. [Season fluctuations of carbamazepine and valproate concentration in patients with epilepsy].
Avakian GN; Oleĭnikova OM; Lagutin IuV; Khromykh EA; Bogomazova MA; Delger AB; Avakian GG
Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(11):34-9. PubMed ID: 24429946
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic modeling of valproate from clinical data in Serbian epileptic patients.
Jankovic SM; Milovanovic JR
Methods Find Exp Clin Pharmacol; 2007 Dec; 29(10):673-9. PubMed ID: 18200330
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of carbamazepine and valproate as monotherapy for early epilepsy and single seizures.
Marson AG; Williamson PR; Taylor S; Maguire M; Chadwick DW
Neurology; 2006 Nov; 67(10):1872-5. PubMed ID: 17130429
[TBL] [Abstract][Full Text] [Related]
16. Pilot study to determine the interaction of oxiracetam with antiepileptic drugs.
van Wieringen A; Meijer JW; van Emde Boas W; Vermeij TA
Clin Pharmacokinet; 1990 Apr; 18(4):332-8. PubMed ID: 2108837
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic interaction between ivabradine and carbamazepine in healthy volunteers.
Vlase L; Neag M; Popa A; Muntean D; Bâldea I; Leucuta SE
J Clin Pharm Ther; 2011 Apr; 36(2):225-9. PubMed ID: 21366652
[TBL] [Abstract][Full Text] [Related]
18. Investigation of phenobarbital-carbamazepine-valproic acid interactions using population pharmacokinetic analysis for optimisation of antiepileptic drug therapy: an overview.
Yukawa E
Drug Metabol Drug Interact; 2000; 16(2):86-98. PubMed ID: 10962642
[TBL] [Abstract][Full Text] [Related]
19. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration.
Dulac O; Alvarez JC
Pharmacotherapy; 2005 Jan; 25(1):35-41. PubMed ID: 15767218
[TBL] [Abstract][Full Text] [Related]
20. The mechanism of the carbamazepine-valproate interaction in humans.
Bernus I; Dickinson RG; Hooper WD; Eadie MJ
Br J Clin Pharmacol; 1997 Jul; 44(1):21-7. PubMed ID: 9241092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
